A merger between US-based healthcare conglomerate Baxter and Sweden-based medical technologies company Gambro will be cleared by the European Commission, say reports. The agreement, signed at $4 billion, was modified when Baxter agreed to divest part of the company worth about one-fifth of its annual turnover, said two unnamed sources. Clearance from the European Commission would make the company the second-largest dialysis equipment manufacturer; reports say the global market is set to grow as obesity and diabetes rates climb. The two companies announced the deal last December.
Featured News
Italian Ski-Pass Operators Agree to €30 Million Payout After Antitrust Probe
Aug 8, 2026 by
CPI
Delaware Court Orders Verisk to Pursue $2.35 Billion AccuLynx Deal Despite FTC Review
Aug 8, 2026 by
CPI
Trump Pushes Back on AI Rules as Congress Weighs Tighter Controls
Aug 8, 2026 by
CPI
Warren Raises Antitrust Concerns Over Private Home Listings
Aug 8, 2026 by
CPI
PlayStation Antitrust Cases Put Closed Console Stores Under Scrutiny
Aug 8, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes